Teijin Pharma Ltd. is a medical products manufacturer. The Company develops, manufactures, and sells pharmaceuticals and medical devices for bone and joint diseases, respiratory diseases, and cardiovascular and metabolic diseases. Teijin Pharma further offers various identical medical services and remedies.
In India, the business of Teijin Pharma Ltd. focuses on Humanized antibodies for treating or preventing cognitive disorders, the process for producing the same, and agent for treating or preventing cognitive disorders using the same, Pyrazole amide derivative, and Pyrazolo[1,5-a]pyrimidine derivatives.
Teijin Pharma Ltd. filed a patent application numbered 201617028844 that is titled PYRAZOLE AMIDE DERIVATIVE. The patent has been filed in the field of Chemicals. This Patent Application has been granted as Patent Number 353718. This invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein: R1, R3, R4, R5, R8, R9, and R12 are as described in description and claims, Y is selected from a C4 to C6 cycloalkyl group, a C6 to C9 bicycloalkyl group and a C6 to C9 spiroalkyl group, all of which are substituted by an R2 group, 0 or 1 R6 group and 0, 1, 2 or 3 R7 groups.
During the patent examination, the Patent Examiner raised objections under Section 3(d) of Patents (Amendment) Act, 2005. Since the cited documents disclose pyrazole amide derivatives structurally similar to the compound formula I and the use of the compound are also for similar activity. Hence, the compounds are considered derivative of a known compound is cited without any distinguishing improved efficacy with reference to the cited ones.
As a response, the Applicant submitted that the claimed compound is novel and inventive in view of the comments presented in the preceding paragraph and structurally distinguishable from the cited prior arts. In view of this, the withdrawal of the objection is respectfully requested.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
